Atrolactamide

Atrolactamide

SCHEMBL31758013

CC(O)(C(N)=O)c1ccccc1.O=C(O)C(O)c1ccccc1

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.58
MAPK1 P28482 1/20 0.58
MAPT P10636 1/20 0.49
KMT2A Q03164 1/20 0.49
CYP2D6 P10635 2/20 0.41
HPGD P15428 1/20 0.41
CYP1A2 P05177 1/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
KIF11 P52732 1/20 0.39
SRC P12931 1/20 0.37
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
EPHX1 P07099 5/20 0.37
ALOX5 P09917 1/20 0.37
AOC3 Q16853 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mandelic Acid SCHEMBL8757198 0.87 LMNA (0.62) LMNAMAPK1MAPTKMT2ACYP2D6
Mandelic Acid SCHEMBL4326804 0.85 LMNA (0.60) LMNAMAPK1MAPTKMT2ACYP2D6
Atrolactamide SCHEMBL78236 0.84 MAPT (0.65) LMNAMAPTKMT2ACYP2D6CYP1A2
Mandelic Acid SCHEMBL1275427 0.78 LMNA (0.86) LMNAMAPK1CYP2D6HPGDCES2
Mandelic Acid SCHEMBL11083521 0.78 LMNA (0.86) LMNAMAPK1KMT2ACYP2D6HPGD
SCHEMBL7563030 0.78 LMNA (0.50) LMNAMAPK1KMT2ACYP2D6HPGD
Atrolactamide SCHEMBL28842804 0.78 MAPT (0.57) LMNAMAPTKMT2ACYP2D6CYP1A2
Mandelic Acid SCHEMBL8876737 0.76 LMNA (0.90) LMNAMAPK1KMT2ACYP2D6HPGD
Mandelic Acid SCHEMBL6056301 0.76 LMNA (0.90) LMNAMAPK1KMT2ACYP2D6HPGD
Mandelic Acid SCHEMBL7279536 0.76 LMNA (0.90) LMNAMAPK1KMT2ACYP2D6HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260008766-A1 EPISULFIDE COMPOUND AND OPTICAL MATERIAL COMPOSITION THEREOF Efirm New Material Co., Ltd. (CN) 2026-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260008766-A1 EPISULFIDE COMPOUND AND OPTICAL MATERIAL COMPOSITION THEREOF LATS1, LATS2, TST LMNA 4519/4885MAPK1 619/4885MAPT 911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.